Bupropion Hydrobromide

3月18日，Nature子刊Nature Metabolism上发表的两篇最新研究揭示了二甲双胍减肥的新作用机制,研究发现，二甲双胍在人类和动物的肠道中能够促进肠道细胞产生称为Lac-Phe的代谢产物。Lac-Phe是基于乳酸和苯丙氨酸合成的代谢分子，人类剧烈运动会导致血液中乳酸水平升高，而Lac-Phe的水平也随之升高，Lac-Phe具有降低食欲的作用，在小鼠模型中长期使用Lac-Phe会降低脂肪组织水平和体重，改善葡萄糖稳态。Nature Metabolism发表的文章评论，与GLP-1类药物相比，二甲双胍的减肥效果更为温和和缓慢。 一直以来，二甲双胍都是治疗2型糖尿病的基石。《二甲双胍临床应用专家共识（2023年版）》中提到，除了降糖，二甲双胍还具有减重、保护心血管、降血脂、改善非酒精性脂肪肝、治疗多囊卵巢综合征、抗肿瘤、改善认知功能、减轻新冠病毒感染等多种功能，但这些大多还停留在临床验证阶段，机制并不十分明确，需要开展进一步更深入的研究来确定其治疗机制以及在不同人群中开展更多的临床研究来证明其潜力。二甲双胍作为一种安全有效的口服降糖药物，通过减少肝脏葡萄糖产生、增加肌肉对葡萄糖的敏感性等机制，可以有效控制血糖水平，改善糖尿病患者的生活质量。据RPDB零售数据库样本药店模块统计，近年来，口服降糖药市场销售额较稳定，2023年样本药店销售额总额为28.25亿元，较2022年同比增长13.3%。图1: 2020-2023样本市场口服降糖药销售额来源：RPDB中国零售药店数据库，中国医药工业信息中心按通用名分类，二甲双胍常年占据零售市场口服降糖药TOP 1，且几年来市场份额占比均超过30%。图2: 2020-2023样本市场口服降糖药TOP10来源：RPDB中国零售药店数据库，中国医药工业信息中心根据样本药店放大模块统计，二甲双胍类药物中2023年全国实体药店销量排名前三的产品分别是盐酸二甲双胍片，2023全年实体药店销售额为14.66亿元；盐酸二甲双胍缓释片，销售额达12.61亿元；吡格列酮二甲双胍片(15mg/500mg)，为3.35亿元。图3: 2023放大市场二甲双胍产品销售额TOP10来源：RPDB中国零售药店数据库，中国医药工业信息中心相信此次二甲双胍减肥机制的明确会助力其销量再创新高。近年来，全球肥胖人数不断增加。前不久，世界肥胖联合会（World Obesity）发布了2024年度《World Obesity Atlas 2024》，预测了2020-2035年世界各国肥胖趋势情况。报告显示，预计到2035年，全球有近33亿成年人为高BMI（超重+肥胖），2020年这一数值为22亿，高BMI成年人数量从2020年的42%预计增加到2035年的54%；对于5-19岁的儿童，高BMI占比从2020年的22%（4.3亿）上升到2035年的39%（7.7亿）。在2020-2035年期间，中国大陆地区预计高BMI成年人数量年增长率为2.8%，儿童的这一数值为2.0%。肥胖人群的不断扩大也为减肥药带来了巨大的市场。据统计，全球减肥药市场规模将从2017年的20亿美元扩大到2025年的64亿美元，2030年预计达到115亿美元。2017-2021年期间，中国的减肥药市场规模从2.5亿人民币增长到30亿元，预计未来几年，中国减肥药市场的规模将在居民体重管理意识的提升以及多种新型减肥药上市的影响下进一步扩大，到2025年预计达87亿人民币。迄今为止，美国FDA共有17款减肥药上市，但部分药物在肥胖患者长期使用过程中因出现一些致命的严重不良反应，11种药物遭美国FDA勒令撤市。目前仍在市的只有6种，包括奥利司他、芬特明/托吡酯、纳曲酮/安非他酮、利拉鲁肽、塞美拉肽、司美格鲁肽。在我国，目前被批准用于减重适应症的药物只有3种。第一款是2000年11月在我国获批上市的OTC（甲类非处方药）奥利司他，是一种长效、强效的特异性胃肠道胰脂肪酶抑制剂；第二款是2023年7月获批的GLP-1类药物，来自华东医药的利拉鲁肽类似物利鲁平；第三款是去年7月紧随其后获批的另一款GLP-1药物，来自仁会生物的贝那鲁肽，是国内第一款获批用于治疗肥胖症的原研药，也是全球唯一的氨基酸序列与人源完全一致的GLP-1类药物。此外，两款重磅GLP-1类药物，诺和诺德的减重版司美格鲁肽注射液Wegovy和礼来的减重版替尔泊肽Zepbound目前在中国均处于III期临床，也即将登录中国减肥药市场。未来谁将成为中国减肥药销量的TOP1选手？让我们拭目以待！END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

Company Introduces Multimedia Resources to Bring Awareness of SAD LAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving time concluded for much of the US on November 5, and as the seasons change and the days grow shorter, many people may find themselves grappling with the onset symptoms of seasonal affective disorder (SAD). SAD is a type of depression that follows a seasonal pattern and most often occurs with the change to the fall-winter season. Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global diversified pharmaceutical company dedicated to advancing global health, is helping to raise awareness about the importance of SAD symptom recognition and dialogue with a healthcare professional. Specifically, Bausch Health has introduced several comprehensive initiatives to raise awareness for SAD symptoms and prevention, including a national television ad for its antidepressant APLENZIN® (bupropion hydrobromide) extended-release tablets, the only FDA-approved bupropion hydrobromide that is indicated for the prevention of SAD. The campaign is designed to inform individuals about SAD symptoms during the autumn and winter months and to encourage people diagnosed with SAD to engage in a dialogue with a healthcare professional about potential prevention and treatment-related strategies as needed. "SAD is a seasonal type of depression that manifests itself in the fall and winter months. When there's less sunlight outside, a person's natural ability to regulate certain chemicals can be disrupted which may impact depression," said Eric Guenin, PharmD, Ph.D., MPH, executive director, medical affairs, Bausch Health. "Prevention is key, when possible, so people must be aware of some of the symptoms of SAD, such as feeling depressed most of the day almost every day, losing interest in activities they once enjoyed, experiencing low energy, facing difficulty sleeping, weight changes, and be encouraged to discuss them with a healthcare professional as preventive treatment options exist." In addition to the ad campaign, there is a revamped APLENZIN website, which features a SAD fact sheet as well as a new patient engagement program called "Real Talk with APLENZIN" that provides subscribers with helpful tools and support. The site also includes a downloadable health questionnaire and "mood tracker" that provides patients practical tools to share and discuss with a healthcare professional, who can determine if there is a seasonal pattern to their symptoms. To learn more about APLENZIN please see Important Safety Information including boxed warning below and visit . About SAD SAD is a type of depression that follows a seasonal pattern. Symptoms often occur during the fall and winter months. SAD is more than the "winter blues," it is a serious mental health condition. When there's less sunlight outside, a person's natural ability to regulate certain chemicals can be disrupted which may impact depression. And that may lead to symptoms of SAD. The seasonal symptoms of SAD can include but are not limited to feeling depressed most of the day, nearly every day; losing interest in activities you once enjoyed; feeling hopeless or worthless; withdrawing socially; overeating, particularly craving carbohydrates; weight gain; and oversleeping. About APLENZIN APLENZIN (bupropion hydrobromide) is an antidepressant indicated for the treatment of major depressive disorder and prevention of SAD. APLENZIN is the only FDA-approved bupropion hydrobromide and offers extensive clinical experience in patients with MDD or SAD. APLENZIN is a once-daily, single tablet available in 3 dosage strengths, with no generic substitute. Recommended dosing for patients with SAD includes initiating treatment in the fall and discontinuing in early spring, as prescribed by a healthcare professional. For more information, visit . INDICATION APLENZIN® (bupropion hydrobromide extended-release tablets) is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder, and for the prevention of autumn-winter seasonal depression (seasonal affective disorder). IMPORTANT SAFETY INFORMATION WARNING: CHANGES IN THINKING AND BEHAVIOR, DEPRESSION, AND SUICIDAL THOUGHTS OR ACTIONS Suicidal Thoughts or Actions and Antidepressant Drugs Antidepressants may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. People who have (or have a family history of) bipolar illness or suicidal thoughts or actions may have a particularly high risk. Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if symptoms such as anxiety, irritability, impulsivity, trouble sleeping, aggressive behavior or suicidal thoughts are new, worse or worry you. APLENZIN has not been evaluated for use in patients under the age of 18. Call your healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling very agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood Although APLENZIN is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking. Some people have had serious side effects while taking bupropion to help them quit smoking, including: New or worse mental health problems, such as changes in behavior or thinking, aggression, hostility, agitation, depression, or suicidal thoughts or actions. Some people had these symptoms when they began taking bupropion, and others developed them after several weeks of treatment, or after stopping bupropion. These symptoms happened more often in people who had a history of mental health problems before taking bupropion than in people without a history of mental health problems. Stop taking APLENZIN and call your healthcare provider right away if you, your family, or caregiver notice any of these symptoms. Work with your healthcare provider to decide whether you should continue to take APLENZIN. In many people, these symptoms went away after stopping APLENZIN, but in some people, symptoms continued after stopping APLENZIN. It is important for you to follow-up with your healthcare provider until your symptoms go away. Before taking APLENZIN, tell your healthcare provider if you have ever had depression or other mental health problems. You should also tell your healthcare provider about any symptoms you had during other times you tried to quit smoking, with or without bupropion. What Other Important Information Should I Know About APLENZIN? Seizures: There is a chance of having a seizure (convulsion, fit) with APLENZIN, especially in people with certain medical problems or who take certain medicines. Do not take any other medicines while you are taking APLENZIN unless your healthcare provider has said it is okay to take them. If you have a seizure while taking APLENZIN, stop taking the tablets and call your healthcare provider right away. High blood pressure (hypertension): Some people get high blood pressure that can be severe while taking APLENZIN. Manic episodes: Some people may have periods of mania while taking APLENZIN. If you have any of the following symptoms of mania, call your healthcare provider: greatly increased energy severe trouble sleeping racing thoughts reckless behavior unusually grand ideas excessive happiness or irritability talking more or faster than usual Unusual thoughts or behaviors: Some patients may have unusual thoughts or behaviors while taking APLENZIN, including delusions (e.g., believe you are someone else), hallucinations (seeing or hearing things that are not there), paranoia (feeling that people are against you), or feeling confused. If this happens to you, call your healthcare provider. Visual problems: Some people are at risk of glaucoma which can present as: eye pain, changes in vision, or swelling and redness around the eye if they take APLENZIN. You should see an eye doctor to determine whether you are at risk prior to starting therapy. Severe allergic reactions: Some patients have severe allergic reactions to APLENZIN. Stop taking APLENZIN and call your healthcare provider right away if you get a rash, itching, hives, fever, swollen lymph glands, painful sores in the mouth or around the eyes, swelling of the lips or tongue, chest pain, or have trouble breathing. These could be signs of a serious allergic reaction. Do not take APLENZIN if you: have or had a seizure disorder or epilepsy have or had an eating disorder such as anorexia nervosa or bulimia are taking any other medicines that contain bupropion, including WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, ZYBAN, or FORFIVO XL. Bupropion is the same active ingredient that is in APLENZIN drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these make you sleepy), benzodiazepines, or anti-seizure medicines, and you stop using them all of a sudden take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid do not take an MAOI within 2 weeks of stopping APLENZIN unless directed to do so by your healthcare provider do not start APLENZIN if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your healthcare provider are allergic to the active ingredient in APLENZIN, bupropion, or to any of the inactive ingredients Although APLENZIN is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking. Before taking APLENZIN, tell your healthcare provider if you have ever had depression, suicidal thoughts or actions, or other mental health problems or any symptoms you had during other times you tried to quit smoking with or without bupropion. Also, tell your healthcare provider about your other medical conditions, including if you: have liver problems, especially cirrhosis of the liver have kidney problems have, or have had, an eating disorder such as anorexia nervosa or bulimia have had a head injury have had a seizure (convulsion, fit) have a tumor in your nervous system (brain or spine) have had a heart attack, heart problems, or high blood pressure are a diabetic taking insulin or other medicines to control your blood sugar drink alcohol abuse prescription medicines or street drugs are pregnant or plan to become pregnant. Talk to your healthcare provider about the risk to your unborn baby if you take APLENZIN during pregnancy, and about registering with the National Pregnancy Registry by calling 1-844-405-6185 are breastfeeding. APLENZIN passes into your milk in small amounts Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Many medicines increase your chances of having seizures or cause other serious side effects if you take them while you are using APLENZIN. The most common side effects of APLENZIN include: trouble sleeping, stuffy nose, dry mouth, dizziness, feeling anxious, nausea, constipation, and joint aches. Click here to read the Medication Guide carefully before you start using APLENZIN. If you have any questions about APLENZIN, ask your healthcare provider or pharmacist. Click here for full Prescribing Information, including Medication Guide and Boxed Warning regarding suicidal thoughts and actions. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also contact Bausch Health Customer Service at 1-800-321-4576. About Bausch Health Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit and connect with us on Twitter and LinkedIn. Media Contact: Kevin Wiggins corporate.communications@bauschhealth.com (908) 541-3785 Investor Contact: ir@bauschhealth.com (908) 541-2102 (877) 281-6642 (toll free) References Hansen BT, et al. Daylight Savings Time Transitions and the Incidence Rate of Unipolar Depressive Episodes. Epidemiology. 2017;28(3):346-353. American Psychiatric Association. Seasonal affective disorder (SAD). . Accessed September 1, 2022. Meesters Y, Gordijn MCM. Seasonal affective disorder, winter type: current insights and treatment options. Psychol Res Behav Manag. 2016;9:317-327. National Institute of Mental Health. Seasonal affective disorder. . Accessed September 1, 2022. APLENZIN (bupropion hydrobromide extended-release) Prescribing Information. Bausch Health Companies Inc. Melrose S. Seasonal affective disorder: an overview of assessment and treatment approaches. Depress Res Treat. 2015;2015:178564. APLENZIN is a trademark of Bausch Health Companies Inc. or its affiliates. Any other product/brand names and/or logos are trademarks of the respective owners. © 2023 Bausch Health Companies Inc. or its affiliates. APL.0132.USA.23 SOURCE: Bausch Health Companies Inc. View source version on accesswire.com: